NEJM 16 Jan 2014 Vol 370 201 Developing and marketing a new drug is a tricky business, but it can be a very lucrative one. AiCuris is a company I hadn’t heard of before, but it seems to specialize in antiviral drugs. For such a company, herpes simplex 2 infection presents a huge market opportunity: […]
Richard Lehman’s journal review—20 January 2014